Quantcast
Channel: Latest Crohn's Disease News on BioPortfolio
Viewing all articles
Browse latest Browse all 2985

Celgene Provides Update on GED0301 mongersen Inflammatory Bowel Disease Program

$
0
0
Celgene Corporation NASDAQ CELG today announced that the GED0301 mongersen phase III REVOLVE trial CD002 in Crohns disease CD and the extension trial SUSTAIN CD004 will discontinue. Celgene has decided to stop the trials following a...

Viewing all articles
Browse latest Browse all 2985

Trending Articles